TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15155119

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finasteride + Doxazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Finasteride alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 0
Study: 12171979

Group type: EXPERIMENTAL
Intervention: urokinase + abciximab
Number of subjects: 26

Group type: COMPARATOR
Intervention: urokinase
Number of subjects: 26
Study: 9722799

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FP ANS) 200 microgram once daily
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once daily
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FP ANS) plus loratadine
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo (aqueous nasal spray plus tablet)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FP ANS)
Number of subjects: 600
Study: 7806687

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 381

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 381
Study: 2527121

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (oral, 1 g once daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (intravenous, 500 mg in 100 ml of physiological saline)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 415478

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, vincristine, prednisone, and doxorubicine or VM 26 (induction chemotherapy course for 15-20 days)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Previous treatment with cyclophosphamide, vincristine, and prednisone only
Number of subjects: 66
Study: 31163332

Group type: EXPERIMENTAL
Intervention: MI‐CBT plus treatment as usual (TAU)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 44
Study: 28433465

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich beverage (440 kcal/300 mL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fat-rich beverage (440 kcal/300 mL)
Number of subjects: 12
Study: 26426421

Group type: EXPERIMENTAL
Intervention: KM2H2 plus standard CBHCP care
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 450
Study: 23688879

Group type: EXPERIMENTAL
Intervention: Intralase FS60 femtosecond laser (Group 1)
Number of subjects: 816

Group type: COMPARATOR
Intervention: Femto LDV femtosecond laser (Group 2)
Number of subjects: 816
Study: 23213766

Group type: EXPERIMENTAL
Intervention: Laryngopharyngeal simulator teaching
Number of subjects: 65
Study: 18824845

Group type: EXPERIMENTAL
Intervention: NT‐proBNP levels
Number of subjects: 982
Study: 17722521

Group type: EXPERIMENTAL
Intervention: Onion extract alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Silicon gel sheet alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of onion extract and silicon gel sheet
Number of subjects: 60
Study: 15108076

Group type: EXPERIMENTAL
Intervention: Mild hypothermic CPB (32 degrees C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normothermic CPB (>35 degrees C)
Number of subjects: 60
Study: 11788126

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10091203

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg once daily for 1 year)
Number of subjects: 1908

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1908

Group type: COMPARATOR
Intervention: Alendronate and Placebo
Number of subjects: 1908
Study: 7529520

Group type: EXPERIMENTAL
Intervention: Aprotinin (1 x 10(6) kallikrein inactivator units (KIU) as an intravenous bolus and 1 x 10(6) KIU added to the pump prime)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% saline placebo (control group)
Number of subjects: 20
Study: 2979255

Group type: EXPERIMENTAL
Intervention: enisoprost 100 micrograms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: enisoprost 200 micrograms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: enisoprost 400 micrograms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: misoprostol 200 micrograms
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 29607623

Group type: EXPERIMENTAL
Intervention: DS-8500a 25 mg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: DS-8500a 75 mg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 28962590

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 733

Group type: COMPARATOR
Intervention: CDAI (Clinical Disease Activity Index)
Number of subjects: 733

Group type: COMPARATOR
Intervention: RAPID3 (Routine Assessment of Patient Index Data 3)
Number of subjects: 733
Study: 26310621

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA) 15 mg/kg body weight
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (0.9% sodium chloride solution)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 90
Study: 23538970

Group type: EXPERIMENTAL
Intervention: venlafaxine ER (75‐300 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: fluoxetine (20‐60 mg/day)
Number of subjects: 0
Study: 21282194

Group type: EXPERIMENTAL
Intervention: Clade 1 HA vaccine followed by clade 2 HA vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerated schedule (days 0 and 7)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schedule of injections at days 0 and 14
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schedule of injections at days 0 and 28
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schedule of injections at days 0 and 6 months
Number of subjects: 0
Study: 19058584

Group type: EXPERIMENTAL
Intervention: Oral penicillin (500 mg bid)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 16553814

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei subsp. casei together with dextran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12663340

Group type: EXPERIMENTAL
Intervention: 10 parts per million (ppm) inhaled nitric oxide (NO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (conventional therapy)
Number of subjects: 40
Study: 11002377

Group type: EXPERIMENTAL
Intervention: 2.5 g plant stanols at lunch
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 2.5 g plant stanols divided over three meals (0.42 g at breakfast, 0.84 g at lunch, 1.25 g at dinner)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (no plant stanols)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 2.5 g plant stanols divided over three meals
Number of subjects: 39
Study: 9296243

Group type: EXPERIMENTAL
Intervention: Zafirlukast (oral administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zafirlukast (aerosol dosing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1301850

Group type: EXPERIMENTAL
Intervention: Ligusticum wallichii
Number of subjects: 158

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 158
Study: 3815712

Group type: EXPERIMENTAL
Intervention: Freely-chosen stride length (FCSL)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Stride length conditions (-10%, -5%, +5%, +10%)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Stride length conditions
Number of subjects: 7
Study: 30074934

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 201

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 201
Study: 27733396

Group type: EXPERIMENTAL
Intervention: FeSO4 (∼8 mg Fe)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: NaFeEDTA (∼8 mg Fe, ∼41 mg EDTA)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Na2EDTA (∼41 mg EDTA)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study: 24485481

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no meditation)
Number of subjects: 19
Study: 23413494

Group type: EXPERIMENTAL
Intervention: Two-layer bandage system (KTwo)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Four-layer bandage system (Profore)
Number of subjects: 187
Study: 20147616

Group type: EXPERIMENTAL
Intervention: Otelixizumab
Number of subjects: 0
Study: 18405977

Group type: EXPERIMENTAL
Intervention: Isometric step muscle actions at 5% MVC
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Isometric ramp muscle actions at 35% MVC
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MMG RMS
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MMG MPF
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MMG RMS and MMG MPF
Number of subjects: 19
Study: 16548860

Group type: EXPERIMENTAL
Intervention: 100% oxygen for 10 min
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 7% sevoflurane in 100% oxygen
Number of subjects: 54

Group type: COMPARATOR
Intervention: Air breathing for 10 min
Number of subjects: 54
Study: 12797340

Group type: EXPERIMENTAL
Intervention: Budesonide 128 g/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 10836006

Group type: EXPERIMENTAL
Intervention: Multimodal treatment for noncomplicated colon and rectal cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for colon adenocarcinoma and rectal cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment for complicated colorectal cancer
Number of subjects: 0
Study: 9369890

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration
Number of subjects: 30

Group type: COMPARATOR
Intervention: No hemofiltration (Control)
Number of subjects: 30
Study: 1562865

Group type: EXPERIMENTAL
Intervention: Home care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 120
Study: 3931806

Group type: EXPERIMENTAL
Intervention: Immediate postoperative radiotherapy
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Optional delayed radiotherapy policy (watched group)
Number of subjects: 1461
Study: 31795035

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Venlafaxine-extended release
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Escitalopram or Sertraline (females only)
Number of subjects: 1008
Study: 29499658

Group type: EXPERIMENTAL
Intervention: Intervention (three home visits)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control
Number of subjects: 201
Study: 27956398

Group type: COMPARATOR
Intervention: AF initiation
Number of subjects: 45
Study: 25099201

Group type: EXPERIMENTAL
Intervention: Dose reduction of risperidone or olanzapine (dose reduced by 50%)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Maintenance group (dose kept constant)
Number of subjects: 31
Study: 22520568

Group type: EXPERIMENTAL
Intervention: Conventional maxillary distraction osteogenesis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Anterior maxillary segmental distraction
Number of subjects: 10
Study: 18702064

Group type: EXPERIMENTAL
Intervention: Couple-based relationship enhancement (RE)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 14
Study: 17488138

Group type: EXPERIMENTAL
Intervention: Community pharmacist-led medicines management service
Number of subjects: 1480

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 1480
Study: 15258006

Group type: EXPERIMENTAL
Intervention: Dronabinol (10 mg daily)
Number of subjects: 24
Study: 11236522

Group type: EXPERIMENTAL
Intervention: Haemodialysis for 2-3 hours, started as early as possible after administration of CM (106 +/- 25 minutes)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 15
Study: 9766780

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment of residual symptoms
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard clinical management
Number of subjects: 40
Study: 8142192

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 759
Study: 3415890

Group type: EXPERIMENTAL
Intervention: Intercostal nerve blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: i.m. papaveretum
Number of subjects: 0
Study: 30536713

Group type: COMPARATOR
Intervention: Placebo after 5 years of alendronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continued treatment after 3 years of zoledronic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FLEX group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study: 28431515

Group type: EXPERIMENTAL
Intervention: Online Life Story Book (OLSB) intervention, guided by a trained volunteer over 5 meetings within 8-10 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (control condition)
Number of subjects: 0
Study: 26317819

Group type: EXPERIMENTAL
Intervention: UFH every 8 hours
Number of subjects: 495

Group type: COMPARATOR
Intervention: enoxaparin every 12 hours
Number of subjects: 495
Study: 24188204

Group type: EXPERIMENTAL
Intervention: Budesonide 100 μg plus oral procaterol 25 μg
Number of subjects: 159

Group type: COMPARATOR
Intervention: Budesonide 100 μg plus placebo
Number of subjects: 159
Study: 20473216

Group type: EXPERIMENTAL
Intervention: Child-centered physical activity skill development program (Activity)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Parent-centered dietary modification program (DIET)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Both programs combined (PA+DIET)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: All groups (Activity, DIET, PA+DIET)
Number of subjects: 165
Study: 19001475

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599

Group type: EXPERIMENTAL
Intervention: Candesartan or Placebo
Number of subjects: 7599
Study: 16733947

Group type: EXPERIMENTAL
Intervention: Forgiveness training program (8 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (wait-listed)
Number of subjects: 25
Study: 15210673

Group type: COMPARATOR
Intervention: Healthy infants (control group)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Sick infants
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Linear regression model
Number of subjects: 162
Study: 11293640

Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg, four times daily for 10 days)
Number of subjects: 4826

Group type: COMPARATOR
Intervention: Co-amoxiclav (325 mg, four times daily for 10 days)
Number of subjects: 4826

Group type: COMPARATOR
Intervention: Co-amoxiclav plus erythromycin
Number of subjects: 4826
Study: 9272793

Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Morphine 0.15 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 12
Study: 8346863

Group type: EXPERIMENTAL
Intervention: loratadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: diphenhydramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: normal controls
Number of subjects: 0
Study: 3568540

Group type: EXPERIMENTAL
Intervention: Ketorolac 90 mg
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 155

Group type: COMPARATOR
Intervention: Morphine 6 mg
Number of subjects: 155

Group type: COMPARATOR
Intervention: Morphine 12 mg
Number of subjects: 155
Study: 30783649

Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Darunavir/cobicistat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All antiretroviral drugs
Number of subjects: 0
Study: 28188678

Group type: EXPERIMENTAL
Intervention: Early stent removal at 5 days (without cystoscopy)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Late stent removal at 6 weeks (with cystoscopy)
Number of subjects: 205
Study: 25940060

Group type: EXPERIMENTAL
Intervention: Radial shock wave therapy plus plantar fascia-specific stretching (Group 2, n = 79)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Radial shock wave therapy alone (Group 1, n = 73)
Number of subjects: 152
Study: 23287551

Group type: EXPERIMENTAL
Intervention: Virtual reality simulation (VRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Web-based modules (Control group)
Number of subjects: 0
Study: 22030569

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections with retractable fixed syringes and needles
Number of subjects: 1240

Group type: COMPARATOR
Intervention: Subcutaneous injections with no needles combined
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Intramuscular injections with retractable fixed syringes and needles
Number of subjects: 1240

Group type: COMPARATOR
Intervention: Intramuscular injections with no needles combined
Number of subjects: 1240
Study: 17614027

Group type: EXPERIMENTAL
Intervention: Running with no fluid (NF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Running with ingestion of a 4 % glucose solution (GLU)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Running with ingestion of a water placebo (PLA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 20
Study: 16941885

Group type: EXPERIMENTAL
Intervention: Low intensity laser treatment
Number of subjects: 0
Study: 14550821

Group type: EXPERIMENTAL
Intervention: 0.75 mg everolimus twice daily
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: 1.5 mg everolimus twice daily
Number of subjects: 634

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 634
Study: 10932507

Group type: EXPERIMENTAL
Intervention: Infertile men
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal men
Number of subjects: 40
Study: 8823459

Group type: EXPERIMENTAL
Intervention: 100 IU per kg of rHuEPO subcutaneously twice a week for 2 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 1389934

Group type: EXPERIMENTAL
Intervention: Amitriptyline (10-50 mg a day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral oxycodone (0.28 mg kg-1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intramuscular oxycodone (0.14 mg kg-1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oxymorphone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Noroxycodone
Number of subjects: 9
Study: 3917584

Group type: EXPERIMENTAL
Intervention: Non-intensive stroke unit
Number of subjects: 293

Group type: COMPARATOR
Intervention: General medical wards
Number of subjects: 293
Study: 31926466

Group type: EXPERIMENTAL
Intervention: Suvorexant
Number of subjects: 2061

Group type: EXPERIMENTAL
Intervention: Gaboxadol
Number of subjects: 2061

Group type: EXPERIMENTAL
Intervention: Subjective TST and subjective number of awakenings
Number of subjects: 2061

Group type: COMPARATOR
Intervention: PSG variables plus patient's age and gender
Number of subjects: 2061
Study: 29253555

Group type: EXPERIMENTAL
Intervention: Listening to music during endurance test
Number of subjects: 19

Group type: COMPARATOR
Intervention: No music during endurance test
Number of subjects: 19
Study: 27368257

Group type: EXPERIMENTAL
Intervention: Automated self‐management monitor (ASMM)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Delayed start group (DG)
Number of subjects: 44
Study: 24736388

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural trait-focused intervention (n=519)
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Control intervention (n=528)
Number of subjects: 1047
Study: 22327097

Group type: EXPERIMENTAL
Intervention: Computerised cognitive behaviour therapy (CCBT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 80
Study: 20172900

Group type: EXPERIMENTAL
Intervention: Bioline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phisio
Number of subjects: 30
Study: 17658985

Group type: EXPERIMENTAL
Intervention: Immediate Treatment (IT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 30
Study: 16108749

Group type: EXPERIMENTAL
Intervention: Caudal block with bupivacaine 1 mL/kg after anesthetic induction
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diclofenac suppository 3 mg/kg postinduction and local anesthetic infiltration at port sites
Number of subjects: 50
Study: 12351933

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 11167952

Group type: EXPERIMENTAL
Intervention: 200 microg intranasal mometasone furoate (MF) once daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 10 mg oral montelukast plus 10 mg oral cetirizine once daily (MON/CZ)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9552083

Group type: EXPERIMENTAL
Intervention: Combined therapy (HRT + etidronate)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HRT alone
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Etidronate alone
Number of subjects: 72

Group type: COMPARATOR
Intervention: Calcium and vitamin D (Control group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HRT, etidronate, combined therapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 72
Study: 7817849

Group type: EXPERIMENTAL
Intervention: Traditional feminine role (marriage, motherhood, housing)
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Living with husband, children, parents and/or parents‐in‐law
Number of subjects: 630

Group type: COMPARATOR
Intervention: Occupational status
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: General Health Questionnaire 60‐items (GHQ‐60)
Number of subjects: 630
Study: 2845694

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.5 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.04 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Atracurium)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Pancuronium)
Number of subjects: 60